Age (years), median (range)
|
53.5 (18–75)
|
54.0 (19–75)
|
Sex, n (%)
|
Male
|
75 (23.1)
|
59 (18.2)
|
Female
|
249 (76.9)
|
265 (81.8)
|
Race, n (%)
|
White
|
299 (92.3)
|
298 (92.0)
|
Mestizo
|
24 (7.4)
|
26 (8.0)
|
Native Peruvian
|
1 (0.3)
|
0
|
Ethnicity, n (%)
|
Hispanic or Latino
|
29 (9.0)
|
34 (10.5)
|
Non-Hispanic or non-Latino
|
295 (91.0)
|
290 (89.5)
|
RA disease duration (years), mean (SD)
|
6.79 (6.76)
|
6.59 (6.81)
|
SDAI at screening, n (%)
|
SDAI ≤ 26
|
30 (9.3)
|
34 (10.5)
|
SDAI > 26
|
294 (90.7)
|
290 (89.5)
|
SDAI, mean (SD)
|
40.0 (11.5)
|
39.8 (11.1)
|
CDAI, mean (SD)
|
39.0 (11.0)
|
38.7 (10.8)
|
DAS28-CRP, mean (SD)
|
5.538 (0.8738)
|
5.547 (0.8525)
|
Tender joint count, mean (SD)
|
20.5 (10.2)
|
20.1 (10.1)
|
Swollen joint count, mean (SD)
|
14.0 (6.33)
|
14.0 (6.46)
|
Subject’s assessment of pain, mean (SD)a
|
69.7 (18.7)
|
70.0 (16.2)
|
Subject’s global assessment of disease activity, mean (SD)a
|
69.8 (17.8)
|
69.6 (16.3)
|
Physician’s global assessment of disease activity, mean (SD)a
|
67.5 (14.7)
|
67.0 (15.5)
|
HAQ estimate of physical ability, mean (SD)
|
1.41 (0.59)
|
1.48 (0.56)
|
CRP (mg/dl), mean (SD)
|
0.975 (1.60)
|
1.10 (1.91)
|
ESR (mm/h), mean (SD)
|
42.3 (15.98)
|
42.9 (16.94)
|